|
1
|
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
|
Arch Intern Med
|
2006
|
7.56
|
|
2
|
Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.
|
Int J Antimicrob Agents
|
2008
|
2.03
|
|
3
|
A Dysregulated Balance of Proinflammatory and Anti-Inflammatory Host Cytokine Response Early During Therapy Predicts Persistence and Mortality in Staphylococcus aureus Bacteremia.
|
Crit Care Med
|
2016
|
1.39
|
|
4
|
Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.
|
J Antimicrob Chemother
|
2005
|
1.30
|
|
5
|
Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa.
|
Antimicrob Agents Chemother
|
2005
|
1.27
|
|
6
|
Regulatory oversight and safety of probiotic use.
|
Emerg Infect Dis
|
2010
|
1.13
|
|
7
|
A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients.
|
J Antimicrob Chemother
|
2010
|
1.04
|
|
8
|
Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients.
|
Antimicrob Agents Chemother
|
2011
|
0.97
|
|
9
|
Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa.
|
PLoS One
|
2012
|
0.97
|
|
10
|
Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.
|
Crit Care Med
|
2014
|
0.91
|
|
11
|
Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.
|
Clin Ther
|
2013
|
0.88
|
|
12
|
Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.
|
Antimicrob Agents Chemother
|
2005
|
0.88
|
|
13
|
Can clinical and molecular epidemiologic parameters guide empiric treatment with vancomycin for methicillin-resistant Staphylococcus aureus infections?
|
Diagn Microbiol Infect Dis
|
2011
|
0.86
|
|
14
|
Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome.
|
J Antimicrob Chemother
|
2008
|
0.86
|
|
15
|
Antivirulence potential of TR-700 and clindamycin on clinical isolates of Staphylococcus aureus producing phenol-soluble modulins.
|
Antimicrob Agents Chemother
|
2011
|
0.82
|
|
16
|
Caspofungin: a potential cause of reversible severe thrombocytopenia.
|
Pharmacotherapy
|
2004
|
0.78
|
|
17
|
Tigecycline induction of phenol-soluble modulins by invasive methicillin-resistant Staphylococcus aureus strains.
|
Antimicrob Agents Chemother
|
2013
|
0.76
|
|
18
|
Letter in response to the Infectious Diseases Society of America's 10 x '20 Initiative.
|
Clin Infect Dis
|
2010
|
0.75
|